Soc. Generale Call 690 LLY 19.07..../ DE000SW9UCV2 /
7/12/2024 9:43:41 PM | Chg.+1.300 | Bid9:59:43 PM | Ask- | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
23.830EUR | +5.77% | 23.740 Bid Size: 250 |
- Ask Size: - |
Eli Lilly and Co | 690.00 USD | 7/19/2024 | Call |
GlobeNewswire
7/1
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studyi...
GlobeNewswire
6/28
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combin...
GlobeNewswire
6/21
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
GlobeNewswire
6/11
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
6/10
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifen...
GlobeNewswire
6/6
Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Laso...
GlobeNewswire
5/30
Sermonix Pharmaceuticals to Present Poster on ELAINE-3 Trial in Progress at ASCO 2024
GlobeNewswire
5/30
Anaqua Annual User Experience Conference to Feature Keynotes from Microsoft, SAP, USPTO, and More
GlobeNewswire
5/24
Gov. Holcomb Joins Lilly to Announce Additional $5.3 Billion Investment at LEAP District
GlobeNewswire
5/16
BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED ...
GlobeNewswire
5/16
Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly
GlobeNewswire
5/13
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update